Characteristics of non-Hodgkin lymphoma arising in HIV-infected patients with suppressed HIV replication

AIDS

Volumn 23, Issue 17, 2009, Pages 2301-2308

  Gérard, Laurence ^a   Meignin, Véronique ^a   Galicier, Lionel ^a   Fieschi, Claire ^a   Leturque, Nicolas ^a   Piketty, Christophe ^b   Fonquernie, Laurent ^c   Agbalika, Felix ^a   Oksenhendler, Eric ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Epstein Barr virus; HIV viral load; Human herpesvirus 8; Non Hodgkin lymphoma

Indexed keywords

LACTATE DEHYDROGENASE; VIRUS RNA;

ADULT; ARTICLE; BURKITT LYMPHOMA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE DURATION; EPSTEIN BARR VIRUS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; KAPOSI SARCOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SURVIVAL RATE; TREATMENT DURATION; VIRUS REPLICATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HERPESVIRUS 4, HUMAN; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOMA, AIDS-RELATED; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; VIRUS REPLICATION;

EID: 70449368834     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328330f62d     Document Type: Article

References (38)

1. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730.
2. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315:1194-1199.
3. Palella FJJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
4. Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, Miller V, Gatell JM, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001; 98:3406-3412.
5. Diamond C, Taylor TH, Aboumrad T, Anton-Culver H. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer 2006; 106:128-135.
6. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar RJ. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20:1645-1654.
7. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretro-viral therapy: prospective cohort study. Swiss HIV Cohort Study. BMJ 1999; 319:23-24.
8. Crum-Cianflone N, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 2009; 23:41-50.
9. PatelP, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728-736.
10. Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, et al. AIDS across Europe, 1994-1998: the EuroSIDA study. Lancet 2000; 356:291-296.
11. Hoffmann C, Wolf E, Fatkenheuer G, Buhk T, Stoehr A, Pletten-berg A, et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lym-phoma. AIDS 2003; 17:1521-1529.
12. Lim ST, Karim R, Tulpule A, Nathwani BN, Levine AM. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. J Clin Oncol 2005; 23:8477-8482.
13. Besson C, Goubar A, Gabarre J, Rozenbaum W, Pialoux G, Chatelet FP, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001; 98:2339-2344.
14. Gerard L, Galicier L, Maillard A, Boulanger E, Quint L, Matheron S, et al. Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival. J Acquir Immune Defic Syndr 2002; 30:478-484.
15. Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22:2143-2153.
16. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The 'Mortalite 2000 and 2005' surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48:590-598.
17. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the prehighly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005; 23:4430-4438.
18. Tirelli U, Spina M, Gaidano G, Vaccher E, Franceschi S, Carbone A. Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antire-troviral therapy. AIDS 2000; 14:1675-1688.
19. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107: 265-276.
20. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332:1186-1191.
21. Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, Knowles DM. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996; 88:645-656.
22. He B, Qiao X, Klasse PJ, Chiu A, Chadburn A, Knowles DM, et al. HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol 2006; 176: 3931-3941.
23. Ambinder RF. Epstein-Barr virus associated lymphoproli-ferations in the AIDS setting. Eur J Cancer 2001; 37:1209-1216.
24. Carbone A, Gloghini A. KSHV/HHV8-associated lymphomas. Br J Haematol 2008; 140:13-24.
25. Levine AM, Seneviratne L, Espina BM, Rock Wohl A, Tulpule A, Nathwani BN, Gill PS. Evolving characteristics of AIDS-related lymphoma. Blood 2000; 96:4084-4090.
26. Bonnet F, Balestre E, Thiebaut R, Morlat P, Pellegrin JL, Neau D, Dabis F. Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France. Clin Infect Dis 2006; 42:411-417.
27. Bruyand M, Thiebaut R, Lawson-Ayayi S, Joly P, Sasso A, Pellegrin JL, et al. Immunodeficiency and risk of AIDS-defining and non-AIDS-defining cancers: ANRS CO3 Aquitaine Cohort, 1998 to 2006. 15th Conference on Retrovirus and Opportunistic Infections. Boston; 3-6 February 2008.
28. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematological and Lymphoid Tissues. Lyon: WHO Press; 2008.
29. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993, 329:987-994.
30. Straus DJ, Huang J, Testa MA, Levine AM, Kaplan LD. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142-low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. J Clin Oncol 1998; 16:3601-3606.
31. Chadburn A, Hyjek E, Mathew S, Cesarman E, Said J, Knowles DM. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol 2004; 28:1401-1416.
32. Engels EA, Pittaluga S, Whitby D, Rabkin C, Aoki Y, Jaffe ES, Goedert JJ. Immunoblastic lymphoma in persons with AIDS-associated Kaposi's sarcoma: a role for Kaposi's sarcoma-associated herpesvirus. Mod Pathol 2003; 16:424-429. (Pubitemid 36618462)
33. Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000; 96:2730-2734.
34. Grulich AE, Wan X, Law MG, Milliken ST, Lewis CR, Garsia RJ, et al. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS 2000; 14:133-140.
35. Carbone A. Emerging pathways in the development of AIDS-related lymphomas. Lancet Oncol 2003; 4:22-29.
36. Pluda JM, Venzon DJ, Tosato G, Lietzau J, Wyvill K, Nelson DL, et al. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol 1993; 11:1099-1107.
37. Grulich AE, van Leeuwen MT, FalsterMO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immuno-suppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59-67.
38. Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296:2823-2831